Compare HLX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | CAPR |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | 231 |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2011 |
| Metric | HLX | CAPR |
|---|---|---|
| Price | $8.64 | $28.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.50 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.3M | 773.2K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $876,561,000.00 | N/A |
| Revenue This Year | $2.05 | N/A |
| Revenue Next Year | $5.46 | $3.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.60 | N/A |
| 52 Week Low | $5.52 | $4.30 |
| 52 Week High | $10.75 | $40.37 |
| Indicator | HLX | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 51.22 |
| Support Level | $8.58 | $27.52 |
| Resistance Level | $10.54 | $30.21 |
| Average True Range (ATR) | 0.34 | 1.33 |
| MACD | -0.09 | 0.26 |
| Stochastic Oscillator | 14.08 | 76.59 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.